Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Yu, Kuwata, Takeo, Zahid, Hasan Md, Hashiguchi, Takao, Noda, Takeshi, Kuramoto, Noriko, Biswas, Shashwata, Matsumoto, Kaho, Shimizu, Mikiko, Kawanami, Yoko, Shimura, Kazuya, Onishi, Chiho, Muramoto, Yukiko, Suzuki, Tateki, Sasaki, Jiei, Nagasaki, Yoji, Minami, Rumi, Motozono, Chihiro, Toyoda, Mako, Takahashi, Hiroshi, Kishi, Hiroto, Fujii, Kazuhiko, Tatsuke, Tsuneyuki, Ikeda, Terumasa, Maeda, Yosuke, Ueno, Takamasa, Koyanagi, Yoshio, Iwagoe, Hajime, Matsushita, Shuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226103/
https://www.ncbi.nlm.nih.gov/pubmed/34237284
http://dx.doi.org/10.1016/j.celrep.2021.109385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226103/
https://www.ncbi.nlm.nih.gov/pubmed/34237284
http://dx.doi.org/10.1016/j.celrep.2021.109385

Ejemplares similares